<DOC>
	<DOCNO>NCT01606748</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics ( PK ) necitumumab combination gemcitabine-cisplatin participant advance malignant solid tumor assess potential drug-drug interaction necitumumab gemcitabine-cisplatin .</brief_summary>
	<brief_title>A Drug-Interaction Study Necitumumab ( IMC-11F8 ) Combination With Gemcitabine-Cisplatin</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have document advanced metastatic malignant solid tumor ( except colorectal tumor KRAS mutation ) resistant standard therapy standard therapy available May measurable nonmeasurable disease Have resolution Grade 0 1 National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.0 ( NCICTCAE 4.0 ) clinically significant toxic effect ( alopecia ) prior chemotherapy , surgery , radiotherapy , hormonal therapy Have Eastern Cooperative Oncology Group performance status ( ECOG PS ) score 0 1 Have adequate hepatic , hematologic renal function If female , surgically sterile , postmenopausal , agree compliant highly effective contraceptive method 6 month treatment period . If male , surgically sterile agree compliant highly effective contraceptive regimen 6 month treatment period Female participant childbearing potential negative serum pregnancy test within 7 day prior first dose study therapy Have receive systemic anticancer agent ( include EGFR tyrosine kinase inhibitor ) device within 28 day prior first dose study therapy The recent anticancer therapy receive participant include either gemcitabine cisplatin ( ) Have receive radiotherapy within 14 day prior first dose study therapy Have receive cytotoxic chemotherapy within 21 day prior first dose study therapy Are receive concurrent treatment another anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiation therapy , chemoembolization , target therapy Are consider surgical candidate ( resectable disease ) Have brain metastasis symptomatic require ongoing treatment steroid anticonvulsant Have narrow blockage large vein Have coronary artery disease uncontrolled congestive heart failure Have uncontrolled angina pectoris , experience myocardial infarction within 6 month prior first dose study therapy Have ongoing active infection ( require treatment ) , include active tuberculosis know infection human immunodeficiency virus Have history significant neurological psychiatric disorder , include dementia , seizure , bipolar disorder Have know drug alcohol abuse If female , pregnant breastfeeding Have major surgery within 28 day prior first dose study medication subcutaneous venous access device implantation within 7 day prior first dose study therapy Are currently enrol , discontinue within 30 day prior first dose study therapy clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced Malignant Solid Tumors</keyword>
	<keyword>Solid Cancers</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>